2Kantarjian H M, Vellekoop L, McCredie KB, et al. Intensive combination chemotherapy(POAP10) and splenectomy in the management ofchronic myelogenous leukemia[J].J Clin Oncol,1985,3(2):192-200.
3Goto T, Nishikori M, Arlin Z, et al. Growth characteristic of leukenic and normalhematopoietic cells in Ph1+ chronic myelogenous leukemia and effects of intensivetreatment[J]. Blood,1982,59(4): 793-808.
4Hartwell L H, Kastan M B. Cell cycle controll and cancer[J].Science,1994,266(5192):1821-1828.
5Buchdunger E, Zimmermann J, Mett H, et al. Selective inhibition of the platelet-derivedgrowth factor signal transduction pathway by a protein tyrosine kinase inhibitor of the2-phenylaminopy-rimidine class[J]Proc Natl Acad Sci U S A,1995,92(7):2558-2562.
6Graham S M, Jorgensen H G, Allan E, et al. Primitive, quiescent,philadelphia-positivestem cells from patients with chronic myeloid leukemia are insensitive to STI-571 invitro[J]. Blood, 2002,99(1):319-325.
7Collins R H Jr, Shpilberg O, Drobysik W R, et al. Donor leukocyte infusions in140patients with relapsed maligancy after allogeneic bone marrow transplantation[J]. J ClinOncol, 1997,15(2):433-444.
8Lu P H, Negrin R S. A novel population of expanded human CD3+CD56+ cells derived from Tcells with potent in vivo antitumor activity in mice with severe combinedimmunodeficiency[J]. J Immunol,1994, 153(4):1687-1696.
9Gordon M Y, Dazzi F, Marley S B,et al.Cell biology of CML cells[J].Leukemia,1999,13(Supple 1):S65-S71.
10Jiang X,Lopez A,Holyoake T,et al.Autocine production and action of IL-3 andgranulocyte colony stimulating factor in chronic myeloid leukemia[J]Proc Natl Acad Sci U SA,1999,96(22):12804-12809.
